Analyst Reco. Neurocrine Biosciences, Inc.

Equities

NBIX

US64125C1099

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 11:11:26 09/03/2026 pm IST			5-day change	1st Jan Change
127.03 ^USD	-0.86%		-3.57%	-9.99%

07:35pm	Neurocrine Biosciences, Inc. Presents at Leerink Global Healthcare Conference 2026, Mar-09-2026 08:40 AM
04/03	Neurocrine Biosciences, Inc. Presents at TD Cowen 46th Annual Health Care Conference, Mar-03-2026 11:50 AM

Analyst Reco.

13/02	UBS Adjusts Price Target on Neurocrine Biosciences to $161 From $178, Maintains Buy Rating	MT
12/02	Neurocrine Biosciences' Ingrezza Remains 'Core Value Driver,' Morgan Stanley Says	MT
12/02	Wedbush Adjusts Neurocrine Biosciences Price Target to $151 From $149, Maintains Outperform Rating	MT
12/02	RBC Trims Price Target on Neurocrine Biosciences to $177 From $180, Keeps Outperform Rating	MT
12/02	Morgan Stanley Trims Price Target on Neurocrine Biosciences to $173 From $175, Keeps Equalweight Rating	MT
23/01	UBS Adjusts Price Target on Neurocrine Biosciences to $178 From $188, Maintains Buy Rating	MT
08/01	Morgan Stanley Downgrades Neurocrine Biosciences to Equalweight From Overweight, Adjusts Price Target to $175 From $173	MT
08/12	RBC Raises Price Target on Neurocrine Biosciences to $180 From $160, Keeps Outperform Rating	MT
01/12	Deutsche Bank Raises Price Target on Neurocrine Biosciences to $152 From $142, Keeps Hold Rating	MT
11/11	Morgan Stanley Trims Price Target on Neurocrine Biosciences to $173 From $178, Keeps Overweight Rating	MT
11/11	Neurocrine Biosciences' Depressive Disorder Drug Fails to Meet Primary Goal in Phase 2 Study	MT
11/11	Neurocrine Biosciences, Inc. Provides Update on Phase 2 Study of NBI-1070770 in Adults with Major Depressive Disorder	CI
29/25/29	Wedbush Raises Price Target on Neurocrine Biosciences to $149 From $143, Keeps Outperform Rating	MT
29/25/29	Deutsche Bank Adjusts Neurocrine Biosciences Price Target to $142 From $140, Maintains Hold Rating	MT
29/25/29	RBC Raises Price Target on Neurocrine Biosciences to $160 From $156, Keeps Outperform Rating	MT
29/25/29	Morgan Stanley Raises Price Target on Neurocrine Biosciences to $178 From $168, Keeps Overweight Rating	MT
20/25/20	RBC Raises Price Target on Neurocrine Biosciences to $168 From $163, Keeps Overweight Rating	MT
17/25/17	Neurocrine Biosciences Presents New KINECT® 4 Post-Hoc Analysis Demonstrating Rapid and Sustained Therapeutic Efficacy of INGreZZA® (valbenazine) Capsules	CI
14/25/14	Wedbush Lifts Price Target on Neurocrine Biosciences to $143 From $141, Keeps Outperform Rating	MT
09/25/09	UBS Raises Neurocrine Biosciences Price Target to $195 From $188, Maintains Buy Rating	MT
08/25/08	RBC Lifts Price Target on Neurocrine Biosciences to $156 From $149, Keeps Outperform Rating	MT
05/25/05	RBC Raises Price Target on Neurocrine Biosciences to $149 From $144, Keeps Outperform Rating	MT
31/25/31	RBC Trims Price Target on Neurocrine Biosciences to $144 From $146, Keeps Outperform Rating	MT
31/25/31	Morgan Stanley Raises Price Target on Neurocrine Biosciences to $158 From $150, Keeps Overweight Rating	MT
31/25/31	Biopharma firm Neurocrine Q2 adjusted EPS beats estimates	RE